The PI3K/Akt/mTOR pathway is known to be deregulated especially in NHL (a primarily B-cell lymphoma in humans) [60], [61], and the response of both this dog and two of our T-cell lymphoma dogs (a much more rare condition in humans) to the high dose of the inhibitor is promising. This evidence concerns the gene AKT1 and non-Hodgkin lymphoma.